Injury minimization after myocardial infarction: focus on extracellular vesicles.
Eur Heart J
; 45(18): 1602-1609, 2024 May 13.
Article
in En
| MEDLINE
| ID: mdl-38366191
ABSTRACT
Despite improvements in clinical outcomes following acute myocardial infarction, mortality remains high, especially in patients with severely reduced left ventricular ejection fraction (LVEF <30%), emphasizing the need for effective cardioprotective strategies adjunctive to recanalization. Traditional cell therapy has shown equivocal success, shifting the focus to innovative cardioactive biologicals and cell mimetic therapies, particularly extracellular vesicles (EVs). EVs, as carriers of non-coding RNAs and other essential biomolecules, influence neighbouring and remote cell function in a paracrine manner. Compared to cell therapy, EVs possess several clinically advantageous traits, including stability, ease of storage (enabling off-the-shelf clinical readiness), and decreased immunogenicity. Allogeneic EVs from mesenchymal and/or cardiac stromal progenitor cells demonstrate safety and potential efficacy in preclinical settings. This review delves into the translational potential of EV-based therapeutic approaches, specifically highlighting findings from large-animal studies, and offers a synopsis of ongoing early-stage clinical trials in this domain.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Extracellular Vesicles
/
Myocardial Infarction
Limits:
Animals
/
Humans
Language:
En
Journal:
Eur Heart J
Year:
2024
Type:
Article
Affiliation country:
Switzerland